Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 1
1977 2
1978 2
1979 2
1981 2
1982 4
1983 3
1985 1
1986 2
1987 1
1991 1
1992 1
1993 3
1996 1
1997 4
1998 4
1999 1
2000 2
2001 2
2002 1
2003 2
2004 2
2005 4
2007 1
2008 5
2009 1
2010 1
2012 2
2013 2
2014 1
2015 3
2016 1
2017 1
2019 1
2020 2
2021 2
2022 1
2023 4
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Więcek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV; ASCEND-D Study Group. Singh AK, et al. N Engl J Med. 2021 Dec 16;385(25):2325-2335. doi: 10.1056/NEJMoa2113379. Epub 2021 Nov 5. N Engl J Med. 2021. PMID: 34739194 Free article. Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Nondilated obstructive nephropathy.
Rascoff JH, Golden RA, Spinowitz BS, Charytan C. Rascoff JH, et al. Among authors: charytan c. Arch Intern Med. 1983 Apr;143(4):696-8. Arch Intern Med. 1983. PMID: 6838293
Eosinophilic peritonitis.
Spinowitz BS, Golden RA, Rascoff JH, Charytan C. Spinowitz BS, et al. Among authors: charytan c. Clin Exp Dial Apheresis. 1982;6(4):187-91. doi: 10.3109/08860228209049850. Clin Exp Dial Apheresis. 1982. PMID: 7182084
Tetracycline nephropathy.
Charytan C. Charytan C. Arch Intern Med. 1978 Dec;138(12):1866. Arch Intern Med. 1978. PMID: 718358 No abstract available.
Controversies in iron management.
Nissenson AR, Charytan C. Nissenson AR, et al. Among authors: charytan c. Kidney Int Suppl. 2003 Nov;(87):S64-71. doi: 10.1046/j.1523-1755.64.s87.10.x. Kidney Int Suppl. 2003. PMID: 14531776 Free article. Review.
Dialysis eosinophilia.
Spinowitz BS, Simpson M, Manu P, Charytan C. Spinowitz BS, et al. Among authors: charytan c. Trans Am Soc Artif Intern Organs. 1981;27:161-7. Trans Am Soc Artif Intern Organs. 1981. PMID: 7331072 No abstract available.
74 results